- Home
- ACTU vs VXRT Comparison
ACTU vs VXRT Comparison
Compare ACTU & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- VXRT
- Stock Information
- Founded
- ACTU 2015
- VXRT N/A
- Country
- ACTU United States
- VXRT United States
- Employees
- ACTU N/A
- VXRT N/A
- Industry
- ACTU
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACTU
- VXRT Health Care
- Exchange
- ACTU NYSE
- VXRT Nasdaq
- Market Cap
- ACTU 135.0M
- VXRT 119.0M
- IPO Year
- ACTU 2024
- VXRT N/A
- Fundamental
- Price
- ACTU $7.47
- VXRT $0.58
- Analyst Decision
- ACTU Strong Buy
- VXRT Strong Buy
- Analyst Count
- ACTU 1
- VXRT 2
- Target Price
- ACTU $20.00
- VXRT $3.00
- AVG Volume (30 Days)
- ACTU 85.1K
- VXRT 9.1M
- Earning Date
- ACTU 05-15-2025
- VXRT 08-07-2025
- Dividend Yield
- ACTU N/A
- VXRT N/A
- EPS Growth
- ACTU N/A
- VXRT N/A
- EPS
- ACTU N/A
- VXRT N/A
- Revenue
- ACTU N/A
- VXRT $47,395,000.00
- Revenue This Year
- ACTU N/A
- VXRT N/A
- Revenue Next Year
- ACTU N/A
- VXRT N/A
- P/E Ratio
- ACTU N/A
- VXRT N/A
- Revenue Growth
- ACTU N/A
- VXRT 433.43
- 52 Week Low
- ACTU $5.51
- VXRT $0.29
- 52 Week High
- ACTU $11.99
- VXRT $1.07
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- VXRT 59.05
- Support Level
- ACTU N/A
- VXRT $0.48
- Resistance Level
- ACTU N/A
- VXRT $0.78
- Average True Range (ATR)
- ACTU 0.00
- VXRT 0.08
- MACD
- ACTU 0.00
- VXRT 0.02
- Stochastic Oscillator
- ACTU 0.00
- VXRT 50.00
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.